MoonLake Immunotherapeutics Q2 Loss Narrows, Phase 3 PsA Trial Meets Clinical Goals

MT Newswires Live

Aug 10

MoonLake Immunotherapeutics (MLTX) reported Monday its Q2 loss narrowed to $0.84 per share, from a loss of $0.87 per share, a year earlier.

Analysts polled by FactSet expected a loss of $0.92 per share.

As of June 30, the company said it had $537.0 million in cash, cash equivalents and short-term marketable debt securities on hand, and expected it could fund operations to mid-2028.

Separately, the company said its phase 3 IZAR-1 trial of sonelokimab in biologic-naive patients with psoriatic arthritis met all clinical endpoints at Week 16.

The company said 42.1% of patients receiving the 60 mg dose with induction achieved an ACR50 response, while 66.5% achieved ACR20 and 41.2% achieved minimal disease activity.

Among patients with skin involvement, 61% achieved PASI90 at week 16, it added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2658931555"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2658931555\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2658931555?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-10 21:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2658931555","market":"sh","top_or_hot":-1,"title":"MoonLake Immunotherapeutics Q2 Loss Narrows, Phase 3 PsA Trial Meets Clinical Goals","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/MLTX\">MoonLake Immunotherapeutics</a> (MLTX) reported Monday its Q2 loss narrowed to $0.84 per share, from a loss of $0.87 per share, a year earlier.</p><p>Analysts polled by FactSet expected a loss of $0.92 per share.</p><p>As of June 30, the company said it had $537.0 million in cash, cash equivalents and short-term marketable debt securities on hand, and expected it could fund operations to mid-2028.</p><p>Separately, the company said its phase 3 IZAR-1 trial of sonelokimab in biologic-naive patients with psoriatic arthritis met all clinical endpoints at Week 16.</p><p>The company said 42.1% of patients receiving the 60 mg dose with induction achieved an ACR50 response, while 66.5% achieved ACR20 and 41.2% achieved minimal disease activity.</p><p>Among patients with skin involvement, 61% achieved PASI90 at week 16, it added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MoonLake Immunotherapeutics Q2 Loss Narrows, Phase 3 PsA Trial Meets Clinical Goals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMoonLake Immunotherapeutics Q2 Loss Narrows, Phase 3 PsA Trial Meets Clinical Goals\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-10 21:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/MLTX\">MoonLake Immunotherapeutics</a> (MLTX) reported Monday its Q2 loss narrowed to $0.84 per share, from a loss of $0.87 per share, a year earlier.</p><p>Analysts polled by FactSet expected a loss of $0.92 per share.</p><p>As of June 30, the company said it had $537.0 million in cash, cash equivalents and short-term marketable debt securities on hand, and expected it could fund operations to mid-2028.</p><p>Separately, the company said its phase 3 IZAR-1 trial of sonelokimab in biologic-naive patients with psoriatic arthritis met all clinical endpoints at Week 16.</p><p>The company said 42.1% of patients receiving the 60 mg dose with induction achieved an ACR50 response, while 66.5% achieved ACR20 and 41.2% achieved minimal disease activity.</p><p>Among patients with skin involvement, 61% achieved PASI90 at week 16, it added.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2658931555","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2658931555","pubTimestamp":1786367289,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"MoonLake Immunotherapeutics  reported Monday its Q2 loss narrowed to $0.84 per share, from a loss of $0.87 per share, a year earlier.Analysts polled by FactSet expected a loss of $0.92 per share.As of June 30, the company said it had $537.0 million in cash, cash equivalents and short-term marketable debt securities on hand, and expected it could fund operations to mid-2028.Separately, the company said its phase 3 IZAR-1 trial of sonelokimab in biologic-naive patients with psoriatic arthritis met all clinical endpoints at Week 16.The company said 42.1% of patients receiving the 60 mg dose with induction achieved an ACR50 response, while 66.5% achieved ACR20 and 41.2% achieved minimal disease activity.Among patients with skin involvement, 61% achieved PASI90 at week 16, it added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MLTX":"MoonLake Immunotherapeutics"},"translate_title":"MoonLake Immunotherapeutics Q2 损失缩小，3 期 PsA 试验达到临床目标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MLTX":1.5},"content_text":"MoonLake Immunotherapeutics (MLTX) reported Monday its Q2 loss narrowed to $0.84 per share, from a loss of $0.87 per share, a year earlier.Analysts polled by FactSet expected a loss of $0.92 per share.As of June 30, the company said it had $537.0 million in cash, cash equivalents and short-term marketable debt securities on hand, and expected it could fund operations to mid-2028.Separately, the company said its phase 3 IZAR-1 trial of sonelokimab in biologic-naive patients with psoriatic arthritis met all clinical endpoints at Week 16.The company said 42.1% of patients receiving the 60 mg dose with induction achieved an ACR50 response, while 66.5% achieved ACR20 and 41.2% achieved minimal disease activity.Among patients with skin involvement, 61% achieved PASI90 at week 16, it added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}